Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329
Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID L0362 CAS No. 231277-92-2

Chemical Name

Synonym GSK572016, GW572016

 $\textbf{Formula} \quad C_{29} H_{26} CIFN_4 O_4 S$

Formula Wt. 581.06

Melting Point

Purity ≥98%

Solubility

 Product ID
 Size

 L0362
 5 mg

 L0362
 25 mg

 L0362
 100 mg

Store Temp -20°C Ship Temp Ambient

Description Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This

compound also downregulates expression of thymidylate synthase in vitro.

References

Janni W, Sarosiek T, Karaszewska B, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014 Jan 9. [Epub ahead of print]. PMID: 24402830.

Kostyal D, Welt RS, Danko J, et al. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol. 2012 Sep;29(3):1486-94. PMID: 21769502.

Kim HP, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009 Jun 16;4(6): e5933. PMID: 19529774.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.